Lantheus to sell CDMO business and Springfield, NJ plant to PharmaLogic; signs Lu-177 dotatate supply deal

Lantheus Holdings, Inc.

Definitive agreement dated Nov. 8, 2026 to sell Lantheus's contract development and manufacturing organization (CDMO) business and its Springfield, New Jersey facility to PharmaLogic Holdings Corp.
No purchase price or other financial terms disclosed; closing is subject to customary closing conditions and regulatory approvals.
Under a long-term supply agreement, PharmaLogic's therapeutic CDMO franchise Agilera will manufacture lutetium Lu 177 dotatate for Lantheus.
Lantheus will provide certain transition services to PharmaLogic immediately after closing.
Company flags risks that conditions may not be satisfied and that anticipated benefits may take longer to realize or involve unexpected costs.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.